Analyzing Gilead Sciences Stock Performance

By Blake Campbell • Thursday, August 29 07:52 • Permanent Link

Large-cap Health Care company Gilead Sciences has moved 2.0% so far today on a volume of 6,202,204, compared to its average of 7,161,874. In contrast, the S&P 500 index moved -1.0%.

Gilead Sciences trades -4.45% away from its average analyst target price of $82.22 per share. The 26 analysts following the stock have set target prices ranging from $68.5 to $119.0, and on average have given Gilead Sciences a rating of buy.

If you are considering an investment in GILD, you'll want to know the following:

Gilead Sciences's current price is 83.3% above its Graham number of $42.87, which implies that at its current valuation it does not offer a margin of safety
Gilead Sciences has moved 2.7% over the last year, and the S&P 500 logged a change of 24.1%
Based on its trailing earnings per share of 0.82, Gilead Sciences has a trailing 12 month Price to Earnings (P/E) ratio of 95.8 while the S&P 500 average is 28.21
GILD has a forward P/E ratio of 10.9 based on its forward 12 month price to earnings (EPS) of $7.19 per share
The company has a price to earnings growth (PEG) ratio of 3.43 — a number near or below 1 signifying that Gilead Sciences is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 5.35 compared to its sector average of 3.69
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Based in Foster City, the company has 18,000 full time employees and a market cap of $97.81 Billion. Gilead Sciences currently returns an annual dividend yield of 3.9%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.